The Study of Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgFUS) Treatment for Adenomyosis

Qi Zhang, Yujia Shen, Linghui Xu, Junhai Zhang, Pu‐Yeh Wu
In: ISMRM Annual Meeting · 2025 · doi:10.58530/2025/2194 · W4414238102
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgFUS) treatment was found to be safe and effective in reducing uterine volume and improving dysmenorrhea in 62 adenomyosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This study evaluated the safety and efficacy of magnetic resonance-guided high-intensity focused ultrasound (MRgFUS) for uterine adenomyosis in 62 patients, monitoring adverse reactions during treatment and assessing changes in uterine size and dysmenorrhea scores pre- versus post-treatment. The authors report that all 62 patients completed MRgFUS successfully without severe adverse reactions, with an average ablation rate of 69.12% ± 17.64%. After treatment, uterine volume and dysmenorrhea scores improved significantly compared with baseline (p < 0.05). The paper is presented as an abstract and does not specify additional limitations such as study design details beyond the safety/efficacy observations. This paper is centrally about adenomyosis — it investigates MRgFUS as a non-invasive treatment for adenomyosis-related dysmenorrhea and uterine changes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Motivation: The symptoms of dysmenorrhea, infertility and hypermenorrhea caused by adenomyosis seriously affect the daily life of patients. Therefore, there is an urgent need for an effective non-invasive treatment of uterine adenomyosis. Goal(s): To investigate the safety and efficacy of Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgFUS) treatment on adenomyosis. Approach: MRgFUS was performed on 62 adenomyosis patients to observe the adverse reactions during treatment, the changes of uterine size and improvement of dysmenorrhea. Results: All 62 patients successfully underwent MRgFUS treatment without severe adverse reactions(average ablation rate 69.12%±17.64%). Post-treatment uterine volume and dysmenorrhea scores showed statistically significant improvements compared to pre-treatment (p<0.05). Impact: MRgFUS is safe and effective in the treatment of uterine adenomyosis, and is a new non-invasive treatment approach.
Full text 1,878 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

#2194 DOI: https://doi.org/10.58530/2025/2194 Qi Zhang1, Yujia Shen1, Linghui Xu1, Junhai Zhang1, and Pu-Yeh Wu2 1Huashan Hospital, Fudan University, Shanghai, China, 2GE Healthcare, Beijing, China, Bei Jing, China

Keywords

MR-Guided Focused Ultrasound, MR-Guided Interventions Motivation: The symptoms of dysmenorrhea, infertility and hypermenorrhea caused by adenomyosis seriously affect the daily life of patients. Therefore, there is an urgent need for an effective non-invasive treatment of uterine adenomyosis. Goal(s): To investigate the safety and efficacy of Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgFUS) treatment on adenomyosis. Approach: MRgFUS was performed on 62 adenomyosis patients to observe the adverse reactions during treatment, the changes of uterine size and improvement of dysmenorrhea.

Results

All 62 patients successfully underwent MRgFUS treatment without severe adverse reactions(average ablation rate 69.12%±17.64%). Post-treatment uterine volume and dysmenorrhea scores showed statistically significant improvements compared to pre-treatment (p<0.05). Impact: MRgFUS is safe and effective in the treatment of uterine adenomyosis, and is a new non-invasive treatment approach. How to access this content: For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library. After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library. After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers. Keywords

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosisdysmenorrheainfertility

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK